‘One and done’ HTA success
The phrase ‘one and done’ has become routine vocabulary within the Tolley team over recent years and has become synonymous with Health Technology Assessment (HTA) success. In a UK HTA context, we use the phrase to refer to a National Institute for Health and Care Excellence (NICE) submission that achieves positive guidance and successful reimbursement […]
Challenges and opportunities in rare disease modelling
In a rare disease context, the uncertainties around evidence can be particularly high. Small patient populations can constrain the feasibility of large-scale recruitment into clinical trials, registries and other sources of real-world evidence are often limited, and established practices in terms of clinical management can be poorly evidenced or highly heterogeneous. The challenges that these […]
Stephen Kay, Amanda Strickson, Jorge Puelles, Ross Selby, Eugene Benson & Keith Tolley. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Ther (2017) 8:251–273.
Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Ther (2017) 8:251–273.
Keith Tolley. What are health utilities? Hayward Medical Publishing (2009).
What are health utilities? Hayward Medical Publishing (2009).
Keith Tolley, Joanne Noble-Longster, Sam Mettam, Rachel Hibbs, Matthew Cawson, Luke Stainer, Tom Snell, Ari Manuel. Exploring the impact of excessive daytime sleepiness caused by obstructive sleep apnea on patient and partner quality of life: a time trade-off utility study in the UK general public. J Clin Sleep Med. 2022;18(9):2237–2246.
Exploring the impact of excessive daytime sleepiness caused by obstructive sleep apnea on patient and partner quality of life: a time trade-off utility study in the UK general public. J Clin Sleep Med. 2022;18(9):2237–2246.
Worsley C, Bianco M, Noble-Longster J, Prentice E, Prowse A, Cooper C, Strickson A. A systematic review of clinical efficacy and safety data in penta-refractory multiple myeloma: findings indicate the challenges for HTA submission. Poster HTA236. Presented at: ISPOR Europe 2023; 12-15 November 2023; Copenhagen, Denmark.
A systematic review of clinical efficacy and safety data in penta-refractory multiple myeloma: findings indicate the challenges for HTA submission. Poster HTA236. Presented at: ISPOR Europe 2023; 12-15 November 2023; Copenhagen, Denmark.
Stainer L, Ryder S, Carr E, Collins C, Arora M, Tolley K. : A structured expert elicitation exercise conducted with UK clinicians to inform and validate inputs for a cost-effectiveness analysis of Filsuvez® gel (birch bark extract) in epidermolysis bullosa. Poster CO106. Presented at: ISPOR Europe 2023; 12-15 November 2023; Copenhagen, Denmark.
A structured expert elicitation exercise conducted with UK clinicians to inform and validate inputs for a cost-effectiveness analysis of Filsuvez® gel (birch bark extract) in epidermolysis bullosa. Poster CO106. Presented at: ISPOR Europe 2023; 12-15 November 2023; Copenhagen, Denmark.
Clare Proudfoot, Raju Gautam, Joaquim Cristino, Rumjhum Agrawal, Lalit Thakur & Keith Tolley. Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review. The European Journal of Health Economics (2023) 24:453–467.
Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review. The European Journal of Health Economics (2023) 24:453–467.
Publication of the SLR and NMA for a non-statin, lipid-lowering therapy for patients with hypercholesterolaemia following successful reimbursement through NICE.
Systematic literature reviews (SLRs) play an essential role in health technology assessment (HTA), providing the basis for the evidence presented in a technology appraisal submission. Methodologically flawed SLRs and/or non-transparent reporting of SLRs can raise suspicion and influence an appraiser’s confidence in the evidence to support the clinical and cost-effectiveness case. Our client required an […]
NICE recommend the first therapy to treat epidermolysis bullosa
BACKGROUND Epidermolysis bullosa (EB) is a rare, inherited skin fragility disorder caused by mutations in genes encoding anchoring proteins of the dermal-epidermal junction. Severe forms of EB, such as dystrophic EB (DEB) and junctional EB (JEB), usually present at birth and are therefore often diagnosed soon after birth, or in early childhood. EB manifests with […]